. Author manuscript; available in PMC: 2013 Mar 15.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 Jul 19;82(4):1367–1375. doi: 10.1016/j.ijrobp.2011.05.027

Table 1.

Distribution of Patients

	Capecitabine/ Irinotecan/RT (n=52)		Capecitabine/ Oxaliplatin/RT (n=52)
Age
Median	57		56
Min-Max	27 – 78		30 – 76
Gender	n	%	n	%

Male	33	63	38	73
Female	19	37	14	27
Race
American Indian/Alaska Native	0	0	1	2
Asian	2	4	0	0
Black or African American	4	8	6	12
White	46	88	45	87
Ethnicity
Hispanic or Latino	3	6	0	0
Not Hispanic or Latino	48	92	49	94
Unknown	1	2	3	6
Zubrod Performance Status^*
0	45	87	36	69
1	7	13	16	31
Distance of Tumor from Anal Verge
≤ 6cm	30	58	30	58
7–12 cm	22	42	22	42
T-stage (clinical)
T3	46	88	45	87
T4	6	12	7	13
N-stage (clinical)
N0	23	44	25	48
N1	23	44	24	46
N2	2	4	0	0
NX	4	8	3	6
AJCC Stage (6^th Edition)
Stage IIA	20	38	21	40
Stage IIB	3	6	4	8
Stage IIIB	23	44	24	46
Stage IIIC	2	4	0	0
Unknown	4	8	3	6

Chi square p-value = 0.034